COMMUNIQUÉS West-GlobeNewswire

AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data
01/10/2026
Recent biotech media features focus on Ampligen’s potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC program OCALA, Fla., Oct. 01, 2026 (GLOBE [...]
Doheny Eye Institute Experts to Share Groundbreaking Insights at the American Academy of Ophthalmology 2026 Annual Meeting
01/10/2026
Doheny-UCLA clinicians will participate in more than 30 educational sessions, scientific papers and posters covering retinal disease, glaucoma, pediatric ophthalmology and other areas of eye care PASADENA, Calif., Oct. [...]
Novonesis completes acquisition of MicroBioGen, strengthening its yeast capabilities
01/10/2026
Novonesis completes acquisition of MicroBioGen, strengthening its yeast capabilities The acquisition adds advanced yeast-breeding expertise with a proven track record in bioethanol and broader potential across [...]
European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀
01/10/2026
PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX₁₀₀ Last month Validation confirms that the application is complete and EMA initiates formal review of D-PLEX₁₀₀ D-PLEX₁₀₀ NDA [...]
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
01/10/2026
SUNNYVALE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today [...]
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
01/10/2026
CEO Discusses How Addition of Accomplished Oncology Drug Developer Strengthens Ernexa Ahead of Clinical Development Following ERNA-101 Data Demonstrating Complete Tumor Clearance and 100% Survival in Combination with [...]
Crohn et Colite Canada investit 1,5 million de dollars dans la recherche sur les MII et les soins futurs
01/10/2026
Quatre équipes de recherche canadiennes étudieront de nouvelles approches pour comprendre, traiter et prévenir la maladie de Crohn et la colite ulcéreuse TORONTO, 01 oct. 2026 (GLOBE NEWSWIRE) -- Le nombre de personnes [...]
Crohn’s and Colitis Canada Invests $1.5 Million to Advance IBD Research and Future Care
01/10/2026
Four Canadian research teams will investigate new approaches to understanding, treating and preventing Crohn’s disease and ulcerative colitis TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- As Canada’s inflammatory bowel [...]
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
01/10/2026
MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration of rexaceract by [...]
Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts
01/10/2026
Press release – No. 19 / 2026 Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts Builds on the Metabolic Frontier 2030 strategy, advancing its ambition to become a leader in obesity and [...]
Amplio Pharma Reports Positive Early Clinical Results for NovoBioJect, Designed to Make the World's Most-Used Rheumatoid Arthritis Drug Work for More Patients
01/10/2026
A single dose of NovoBioJect increased the active form of methotrexate inside patients' immune cells by 38%, a first step toward a potential next-generation first-line treatment for rheumatoid arthritis First clinical [...]
Allogenetics Appoints Dr. Olaf Schermeier as Chairman of the Advisory Board
01/10/2026
Hanover, Germany, October 01, 2026 – Allogenetics today announced the appointment of Olaf Schermeier, PhD, as Chairman of its Advisory Board. Dr. Schermeier brings more than 25 years of industry experience, including [...]
Rakovina Therapeutics Partners with Boston-based Celvion Therapeutics to Leverage AI and Real-World Clinical Data for Precision Cancer Drug Development
01/10/2026
Collaboration to identify optimal combination therapies, predictive biomarkers and patient populations for Rakovina’s ATR inhibitor program VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Rakovina [...]
Kestra Medical Technologies Earns Five-Star Rating on Newsweek’s List of America’s Greatest Mid-Market Companies
01/10/2026
KIRKLAND, Wash., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, has earned a five-star rating on Newsweek ’s list of [...]
RadNet and WIN-NextGen™ Form a Collaboration to Inspire the Next Generation of Medical Imaging Professionals
01/10/2026
New program introduces students and young adults to careers in radiology through mentorship, digital experiences and hands-on learning. OWINGS MILLS, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a [...]
Nxera Announces Successful Resolution of miniG Patent Infringement Action
01/10/2026
Tokyo, Japan and Cambridge and London, UK, 30 September 2026 – Nxera Pharma Co., Ltd. (“Nxera Pharma” or “the Company”; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma UK Limited (“Nxera”) has entered [...]
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
01/10/2026
-- Favorable safety and tolerability profile maintained through up to 60 weeks of treatment with ontunisertib in Fibrostenosing Crohn’s disease (FSCD) patients -- -- Low annualized FSCD-related event rate of 3%, with [...]
Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026
01/10/2026
Novo reports analysis from STEP UP trial sub-population in which most participants with elevated liver fat achieved improved liver health after 72 weeks of Wegovy® (injectable semaglutide 7.2 and 2.4 mg) treatment. 9 in [...]
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
01/10/2026
- New Phase 1 data highlight flexibility of injection site for ribupatide injection - Four additional oral presentations from Hengrui Pharma add to the clinical evidence behind Kailera's pipeline WALTHAM, Mass., Oct. 01 [...]

Pages